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What you need to know
• Finding a “health risk” via direct-to-consumer (DTC) genetic testing
often does not mean that a patient will go on to develop the health
problem in question
• DTC genetic tests might report false positives (artefacts)
• “Reassuring” results from DTC genetic tests might be false negatives
• Make sure you are confident in the provenance and interpretation of a
genetic result before you base any clinical decisions on it
• If your patient meets criteria for referral to clinical genetics, refer
regardless of the results of their DTC genetic test
Direct-to-consumer (DTC) genetic tests are sold online and in
shops as a way to “find out what your DNA says.”1 2 Testing
kits typically contain instructions and equipment for collecting
a saliva sample, which customers post to the DTC company for
analysis.
Some DTC genetic tests promise insights into ancestry or disease
risks; others claim to provide information on personality, athletic
ability, and child talent. However, interpretation of genetic data
is complex and context dependent, and DTC genetic tests may
produce false positive and false negative results.
Anyone concerned about a result from a DTC genetic test might
turn to their general practitioner (GP) or other primary healthcare
provider for advice. This practice pointer aims to help clinicians
in this scenario and explains what sort of health information is
provided by these tests, their limitations, and how clinicians
can respond to common questions about them.
What is a DTC genetic test?
Most DTC genetic tests don’t sequence the whole genome. They
typically use a method called SNP-chip genotyping, which
checks for the presence or absence of specific variants
throughout the genetic code, such as particular single nucleotide
polymorphisms (SNPs), or small insertions or deletions.
SNP-chip genotyping detects common genetic variants well,
but when SNP-chips detect very rare variants these are often
false positives (ie, they are not really present in the person’s
DNA).3
Genome sequencing is another method becoming more widely
used in DTC genetic tests. These tests sequence almost the entire
genetic code and identify the variants present within it. However,
detecting variants is not the same as knowing their clinical
effects—clinical interpretation of genetic variants is challenging
and depends on context.
The appeal of DTC genetic testing
People might be drawn to DTC genetic testing in the hope that
it will provide clear cut information about their future health.
This idea may be reinforced by advertising. For example, a
recent analysis of advertising of DTC genetic tests noted that
some tests were presented as potentially empowering, with the
decision to take them portrayed as responsible—a way that
people can take an active role in managing their own health.4
The “personalised medicine” that genetic testing promises is
often portrayed in an optimistic light by the mainstream media,5
and genetic technology is generally presented as highly accurate.
As a result, people may perceive genetic testing as clearly
predictive, and expect that results will help them plan for the
future.6 Our research group recently conducted a YouGov survey
of around 2000 people in the UK, and found that the most
common word that people chose to describe genome sequencing
in healthcare was “informative.”7 A discussion with a patient
considering having a genetic test is outlined in box 1.
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Box 1: Things you might discuss with a patient who is
considering a DTC genetic test
Why do you want the test?
If you have a specific clinical question (grounded in a personal or family history
of a likely genetic condition) for which NHS genetic testing might be available,
you would probably be better off accessing genetic testing via the NHS than
via a DTC company. If you do not have a specific question, then discussing
the pros and cons of particular tests is outside the scope of standard clinical
practice.
Imagine receiving a result you are concerned about
Does the DTC genetic testing company have real people you can talk to? Are
they qualified (eg, genetic counsellors) to advise in response to your clinical
concerns?
If you are worried by the results of your test or want further advice, it might
be hard to access this via the NHS.
Have you read all the information and small print about the test?
Sometimes tests have substantial limitations. If you are worried about a genetic
condition in your family, is the DTC genetic test you are thinking about thorough
enough to properly check this? (see ‘What are the limitations of DTC genetic
tests?)
Could your decision to have a test affect your family?
DTC genetic tests sometimes reveal information that could be relevant to your
family—such as a health risk that might run in the family, or that family
relationships are different from what you expected. Have you told your family
that you are thinking about having a genetic test?
Are you happy with what the DTC company might do with your
data?
DTC companies might collect, store, sell, or undertake research on your
genetic data. Do you find that acceptable? Do you know who might have
access to your data?
More information for people considering buying DTC genetic tests can be
found on the Genetic Alliance website (https://www.geneticalliance.org.uk/
information/service-and-testing/direct-to-consumer-genetic-testing/) and the
Association of Genetic Nurses and Counsellors website (https://www.agnc.
org.uk/info-education/documents-websites/).
What health information do DTC genetic
tests provide?
DTC genetic tests might provide a range of health information:
• Polygenic risk scores—combine many different common
variants across the genome to place someone in a broad risk
category, eg, “your genes predispose you to weigh about 3%
more than average.” The validity and utility of these risk scores
for predictive clinical purposes is hotly debated. In our opinion,
although polygenic scores may be useful in researching the
causes of disease, or stratifying populations into higher and
lower risks, they are rarely able to usefully predict disease.8
• Genotype at specific points—looks at specific variants that
influence the chance of developing particular diseases, eg, “you
have two copies of the ε4 variant in the APOE gene. People
with this result have an increased risk of developing late onset
Alzheimer’s disease.” This type of testing can also be used to
identify variants that affect drug metabolism.
• Carrier screening—looks at specific variants to identify
people who are carriers for particular recessive genetic
conditions, eg, “one variant detected in the CFTR gene. If you
and your partner are both carriers, each child may have a 25%
chance of having this condition.” Many carrier tests are ancestry
specific: they test for specific carrier variants common in a
particular ancestral group. If someone with a different ancestry
were a carrier, this would probably not be detected as it would
likely be due to a different carrier variant (which the test would
not check).
• Uninterpreted “raw” genetic data—some DTC genetic test
companies provide access to uninterpreted genetic data.
Customers can download their data and seek an interpretation
using third party services.9 These usually work by cross
referencing the data against freely available genetic databases
and constructing a report based on interpretations in these
databases (which may not be up to date).10 They may report
variants and disease risks that were not reported or referred to
by the original DTC genetic test company, and might repurpose
raw data from tests designed to answer other questions, such as
ancestry, to try to provide health information.
What are the limitations of DTC genetic
tests?
Predictive value is low when there is no family
history of disease
Jake bought a DTC genetic test online while researching his
family history. He enjoyed learning about his ancestry so
decided to pay for an optional health report. He was very upset
to find that: “you have one variant detected in the LRRK2 gene.
People with this variant have an increased risk of developing
Parkinson’s disease.” Jake had no family history of Parkinson’s
disease.
If a “disease-causing” or “disease-predisposing” genetic variant
is found in a person with no medical or family history of the
corresponding disease, it may be that there are currently
unmeasurable protective genetic (or other) factors in that
person’s family that mean that the variant is less likely to lead
to disease in that person. Most people with apparent “positive”
results will not go on to develop the related condition.
The predictive meaning of a “disease-causing variant” is often
much reduced when found outside the context of a family history
of the relevant disease.11 For example, a study of people with a
genetic form of diabetes found that up to 75% of those who
carry a particular variant (R114W) in the HNF4A gene
developed diabetes by age 40.12 A recent study looking at the
same R114W variant in UK Biobank participants who were not
pre-selected as having diabetes showed that only 10% developed
diabetes by age 40.11 Even if a person does have a family history,
identifying a “high genetic risk” via DTC genetic testing does
not mean that they will definitely develop the condition.
False positives are common, especially where
third party interpretation services are used
Aoife was given a DTC ancestry test for Christmas. She sent
her raw genetic data to an online interpretation service. This
reported that she had a disease-causing BRCA1 variant
(increasing her risk of breast and ovarian cancer). Aoife did
not have a strong family history of breast or ovarian cancer.
She asked her GP to refer her to a breast surgeon. She met the
surgeon, who booked a date for her surgery. Her GP also
referred her to a clinical genetics service, which arranged NHS
testing to check that the BRCA1 variant was really present in
Aoife’s DNA—it wasn’t. The online interpretation service had
reported a false positive result. Aoife’s operation was cancelled
but she still felt anxious about her cancer risk.
False positive results can arise for a number of reasons. The
quality control for DTC genetic tests is variable. Some tests
may be more vulnerable than NHS testing to issues like sample
“miscalls,” where initial analysis appears to detect a particular
genetic variant but subsequent scrutiny shows that it is an
artefact. Results found via third party interpretation services
need particular care. This is because the “raw data” that such
services interpret will contain artefacts,13 and because the
databases used to interpret the data may not be up to date (so
might classify variants incorrectly based on outdated evidence).10
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The SNP-chip genotyping method that most DTC genetic tests
use is unreliable at testing for very rare disease-causing genetic
variants. A recent study looking at BRCA1 and BRCA2 genes
in UK Biobank participants found that 96% of disease-causing
very rare variants identified by SNP-chip genotyping were false
positives.3
Reassuring results can be false negatives
Lily had treatment for breast cancer in her 40s, and her mother
died of ovarian cancer in her 50s. Lily was concerned about an
inherited cause, but also wanted to help conserve NHS
resources, so she bought a DTC test that included a BRCA
screen. She was delighted by the result: no variants were found
in BRCA1 or BRCA2. Lily’s GP explained that many DTC BRCA
screens only screen for a small proportion of the possible
variants in these genes, and referred her to clinical genetics in
view of her family history. NHS genetic testing found that Lily
had a BRCA1 variant that conferred a high lifetime risk of
cancer.
DTC genetic tests tend to prioritise breadth over detail. For
example, the 23andMe “genetic health risk” report for BRCA1
and BRCA2 currently only checks for three disease-causing
variants mainly relevant for people with Ashkenazi Jewish
ancestry; this approach would miss in the region of 80% of
people with disease-causing BRCA variants in the general
population as there are thousands of different disease-causing
BRCA variants that the test does not check for.14-17
Widespread use of phrases such as “having the gene for X”
means that many people think that there is just one BRCA test
that checks if you’ve “got the BRCA gene.” This is incorrect: a
BRCA test can range from a spot-check for a handful of specified
variants, to a thorough examination of the sequence of both
BRCA genes looking for a whole range of possible variants. If
your patient has a personal or family history such that you would
usually refer to clinical genetics, do this even if they have a
reassuring result from a DTC genetic test.
How do people interpret their DTC genetic
test results?
Genetic data are complicated, and can easily be misinterpreted.
DTC genetic tests are sold as providing answers, and patients
may understandably expect that their results will be clearly
predictive of future health. These expectations, driven by
marketing and media coverage, leave people at risk of
over-interpreting results from DTC genetic testing.
One common pitfall is to compare the result to a “zero risk,”
rather than population risk. For example, the Secretary of State
for Health declared that having a genetic test “may have saved
my life,” after his polygenic risk score identified a 15% risk of
developing prostate cancer by age 75. Experts disputed the
usefulness of this result—and his interpretation of it—given
that the average lifetime risk of a man developing prostate cancer
is 18%, and more men die with, than from, prostate cancer.18
Careful framing of results (for example, comparison with
population risks) may mitigate the risk of over-interpretation.
However, this relies on information being provided in an
accessible manner (fig 1); furthermore, users need to know how
important it is to read the information, which may not be obvious
in the context of a societal discourse, which tends to present
genetic results as strongly predictive. The assumption that DTC
genetic testing empowers people to reduce their future disease
risk is undermined by evidence that suggests that learning about
genetic predisposition to particular diseases rarely leads to
sustained lifestyle change.19
DTC genetic tests are often accessed without discussion with a
health professional, so there is little opportunity to address
potential mismatches between expectation and reality in advance
of testing. Often, relevant and important information regarding
the limitations of tests is available on DTC genetic testing
websites, but it is easy to see how their disclaimers might be
perceived as extensive and tedious lists of terms and conditions,
which many people might not engage with in detail.
When should you consider onward
referral?
Patients might ask you about a wide range of “positive”
results—most will not need referral to clinical genetics. Your
regional clinical genetics service may have a local policy
regarding DTC genetic test results, and guidance from the Royal
College of General Practitioners is expected to be published
later this year.
DTC genetic test results should not be used to inform health
decisions without further scrutiny. For patients said to have
“disease-causing” or “likely disease-causing” variants in genes
associated with conditions for which early detection may be
possible and/or treatment is available (eg, BRCA1, BRCA2,
MLH1), inform the patient that further testing often shows that
DTC genetic test results are inaccurate, so they might need a
blood test to confirm or refute their result, and they might not
be offered a genetics appointment.
Refer anyone with a medical or family history where you would
otherwise offer a genetics referral (ie, refer regardless of
“reassuring” results from a DTC genetic test). If in doubt,
contact your regional clinical genetics service to discuss whether
referral is appropriate.
If a patient who has taken a DTC genetic test presents with
symptoms that they are concerned about (or that they think are
explained by the DTC genetic result), assess and investigate the
symptoms in the same way that you would for any other patient.
If the DTC genetic result would change a patient’s clinical
management if it were correct, it needs to be confirmed in an
accredited laboratory.
What to say to patients
When a patient presents with a DTC genetic test result, they
may find an explanation of some of the issues discussed in this
article helpful. Patients might understandably take results at
face value, so it may be useful to discuss possible sources of
error in DTC genetic tests (fig 2). Shifting the conversation
from discussing genetic risk to addressing modifiable lifestyle
factors can be an important part of the consultation.
How patients were involved in the creation of this article
We met the Patient and Public Involvement group at University Hospitals
Southampton NHS Foundation Trust to discuss how patients might react to
receiving concerning DTC test results, their expectations as to how the NHS
should respond, and their views regarding what information might be helpful
to discuss with patients. These discussions helped inform every section of
the article but were especially key for shaping the section “What to say to
patients.” We had 38 responses to a survey on social media about what people
might expect from DTC genetic tests, and how they might respond to results.
This helped inform the sections “What might people expect from DTC genetic
tests?” and “Wider questions,” which reflect some of the issues raised by the
survey respondents.
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• What might you ask if a patient told you they were considering buying
a DTC genetic test?
• What might you say to a patient who booked an appointment to discuss
a DTC genetic test result indicating a high genetic risk of prostate
cancer?
• What would you say to a patient who started smoking again after
receiving a reassuring health report from a DTC genetic test?
Wider questions
• How can we raise public awareness that many genetic results are not
clear cut, and may not substantially shift a person’s pre-existing risk of
disease?
• How can we ensure that patients with personal or family histories
suggesting a genetic condition are not falsely reassured by DTC genetic
test results?
• How should additional healthcare costs arising from DTC genetic tests
be funded? What regulation might be helpful?
How this article was made
We developed fictitious cases to illustrate some of the issues with DTC genetic
tests, based on recent referrals to our regional genetics department,
discussions at GenethicsUK (a forum to discuss ethical issues in genomic
medicine – www.genethicsUK.org), and cases notified to the British Society
of Genomic Medicine. Two of the vignettes discuss BRCA results as referrals
to clinical genetics about DTC genetic test results currently most commonly
relate to BRCA variants.
Information relating to the results that DTC genetic tests commonly provide,
and to the technology commonly used, is based on accessing websites for
various popular DTC genetic testing companies. DTC genetic testing is a
rapidly expanding market and many different tests are available, which use
various analyses and reporting practices, so inevitably the information in this
article cannot be comprehensive.
RH drafted the article; GC edited clinical cases, referral criteria, and facilitated
PPI involvement; LF contributed to clinical cases and fig 2; AF edited the
article and advised on development of figures; CW adapted the article to
improve technical accuracy; AL conceived of article following cases arising in
clinical practice and edited draft as a whole.
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Fig 1 “Genetic risk” for common health conditions (adapted from Jehannine Austin’s “jar model” used in psychiatric genetic
counselling20)
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Fig 2 The process of DTC genetic testing, from consumer decision to test through to receiving results
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